



MAYNE PHARMA ANNOUNCES DEMAND-DRIVEN, MAJOR EXPANSION OF ADELAIDE APOTHECARY

Key Points

- New leased facility in Lexington, Kentucky to meet strong demand for Adelaide Apothecary fulfilment services with an initial investment into manufacturing equipment at the new facility of approx. US\$0.2 million
- Increases annual capacity over two planned phases to over 2.5 million prescriptions per annum (one shift, five days a week), an approx. seven-fold increase in capacity from the current facility
- Subject to further increases in demand, a second shift can be added as required
- New facility to support Adelaide Apothecary's role as a high-volume, automated specialty pharmacy fulfilment centre; expected to commence operations in early 2027
- New facility reflects strong prescription volumes following launch of DistributeRx in March, which significantly exceeded expectations, driving a 73% increase in prescriptions relative pre-launch volumes in February

18 May 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), is pleased to announce that its wholly owned specialty pharmacy, Adelaide Apothecary, will relocate and expand its fulfilment operations to a new facility in Lexington, Kentucky, designed to support the next phase of growth for the Company's wholly owned subsidiary, DistributeRx which launched operations in March 2026.

Adelaide Apothecary, a wholly owned subsidiary of Mayne Pharma, has secured a new lease over a facility in Lexington, Kentucky representing approximately four times the area of the current premises, also in Lexington. The new premises will facilitate Adelaide Apothecary's strategy as a high-volume, automated specialty pharmacy fulfilment centre, and is structured around a scalable, modular automation plan as part of the new equipment fit out. At maximum automation build-out, the facility can support a monthly prescription volume that represents a transformational step-change relative to current throughput, thereby positioning Adelaide Apothecary as one of the few high-volume independent specialty pharmacies serving the Dermatology and Women's Health categories in the US.

Mr Daniel Moore, President of DistributeRx commented *“Adelaide Apothecary's expansion unlocks the full potential of what DistributeRx was designed to do, which is to connect patients and prescribers directly to a best-in-class dispensing facility without the cost and complexity of the traditional specialty pharmacy model. The additional capacity and automation will allow us to serve significantly more patients in a more rapid and convenient manner, which is exactly what prescribers and patients are demanding in light of the complexities of the US Healthcare system generally. In turn, we expect to increase the number and rate of referrer prescriptions coupled with higher patient compliance and repeat ordering behaviour that is beneficial to our scale and margins over time.”*

Mr Aaron Gray, CEO of Mayne Pharma said *“The expansion of Adelaide Apothecary is a direct expression of our confidence in the Mayne Pharma disintermediation strategy led by DistributeRx and our commitment to significantly reduce friction that exists for patients across the pharmacy distribution and reimbursement system in the US. By investing in our own dispensing infrastructure, we are building a durable commercial asset that improves patient access, improves our net sales, and gives Mayne Pharma a structural advantage that elevates as DistributeRx prescription volumes grow. Simplifying the distribution channel via our own cash-based pharmacy is a competitive advantage that very few life sciences companies have and this expansion is our commitment to leveraging the opportunity ahead.”*

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia



DistributeRx is Mayne Pharma's direct-to-patient distribution platform with Adelaide Apothecary serving as Mayne Pharma's licensed pharmacy arm driving cash pay fulfillment of patient prescriptions as part of the Company's overall disintermediation strategy.

Mayne Pharma anticipates the new leased facility in Lexington will require approximately US\$0.2 million in initial manufacturing equipment with up to a US\$2 million in total investment to complete Phase 1 of the expansion. Additional capital expenditures on Phase 2 of the expansion relating to automated conveyance and fulfilment infrastructure is expected to be up to US\$2 million.

The market opportunity for direct-to-patient and virtual pharmacy fulfilment continues to expand, underpinned by structural shifts in the US healthcare industry. Independent research has estimated the global ePharmacy market at US\$114 billion in 2025, which is forecast to grow to US\$252 billion by 2030 (CAGR 17%), driven by rising consumer adoption of digital pharmacy and home delivery.¹

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair.

Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)


About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

About Adelaide Apothecary

Adelaide Apothecary is a wholly owned subsidiary of Mayne Pharma Group Limited (ASX: MYX) and operates as a fully licensed mail order and specialty pharmacy based in Lexington, Kentucky. Licensed across all 50 US states and the District of Columbia, Adelaide Apothecary provides patients with nationwide prescription fulfilment.

¹ Source: Precedence Research





Adelaide Apothecary serves as the cash fulfilment entity for DistributeRx, Mayne Pharma's proprietary healthcare solution platform.

About DistributeRx

DistributeRx is a healthcare solutions company that partners with manufacturers to streamline the prescription distribution process and expand patient access to medications. From strategic access programs and product support to streamlined pharmacy services, DistributeRx is committed to improving product accessibility for prescribers and patients and driving success. DistributeRx is a wholly owned subsidiary of Mayne Pharma.

Important information

This announcement contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward-looking statements use words such as 'potential', 'expect', 'anticipate', 'intend', 'plan', 'target' and 'may', and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Subject to the Company's continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward-looking statements. The factors that may affect the Company's future performance include, among others: changes in economic conditions; changes in the legal and regulatory regimes in which the Company operates; litigation or government investigations; decisions by regulatory authorities including approval of our products as well as their decisions on label claims; competitive developments affecting our products; changes in behaviour of major customers, suppliers and competitors; interruptions to manufacturing or distribution; acquisitions and divestitures; the success of research and development activities and research collaborations and the Company's ability to protect its intellectual property.

